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In the present study, 4-((1H-benzo[d][1,2,3]triazol-1-yl)methylamino)-N-(2,3-diphenyl-5-aryl-3,3a-dihydro-2H-pyrazolo 
[3,4-d]thiazol-6(5H)-yl)benzamide IVa-h has been synthesized by reaction between various 4-((1H-benzo[d][1,2,3]triazol-
1-yl) methylamino)-N-(5-arylidene-4-oxo-2-phenylthiazolidin-3-yl)benzamides IIa-h with phenyl hydrazine. The reaction
of 4-((1H-benzo[d][1,2,3]triazol-1-yl)methylamino)-N-(4-oxo-2-aryl thiazolidin -3-yl) benzamide Ia-h with benzaldehyde
yields IIa-h. All the newly prepared compounds have been characterized by various spectroscopic techniques and screened
for their in vitro antimicrobial and antioxidant activity. The investigation of anti microbial screening data reveals that most
of the compounds tested have demonstrated moderate to good activity. Most of the heterocyclic derivatives bearing two
hydroxyl groups on the phenyl ring show excellent antioxidant activity in comparison with ascorbic acid.
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Number of organic compounds contains heterocycles 
as main structural moiety1. Heterocyclic moieties are 
most frequent in naturally occurring compounds and 
are significant because of their considerable biological 
efficacies that embrace anticancer2, cytotoxic3,  
anti-malarial4, anti-microbial5, anti-inflammatory6, 
anti-oxidant7 and many more8,9. 
Organic compounds bearing thiazoles of different 
pharmacodynamic moieties have anti-inflammatory10, 
antiviral11, antitumor12, herbicides13, and fungicides 
activities and antimicrobial activity14-16. 
Thiazolo - imidazole fused heterocyclic compounds 
explain various biological activities such as, antifungal, 
anthelmintic activity17, anti-HIV-1 activity18, as potent 
cytostatic agents19, immunomodulatory and anticancer 
activities20. 
Experimental Section 
All chemicals used were of laboratory grade. 1H 
and 13C NMR spectra were recorded in DMSO-d6 or 
CDCl3 solutions on a BRUKER 400-MHz spectrometer, 
and chemical shifts were expressed as part per million 
(ppm; δ values) against tetramethylsilane as internal 
reference (TMS). The Infrared spectra (ν,cm-1) were 
obtained with a Perkin−Elmer 1650 FTIR spectrometer 
in KBr pellets. Mass spectra (MS) were recorded on 
EI +Q1 MSLMR UPLR. Elemental analyses were 
performed on an ECS 4010 Elemental Combustion 
System and the results were within the accepted range 
(±0.40) of the calculated values. All melting points 
were determined on an Electro-thermal IA 9100 
apparatus and were uncorrected. Progress of reactions 
was monitored by the of thin-layer chromatography 
(TLC). All the reagents and solvents were of the 
commercial quality and purchased from Merck, Fluka 
and local companies. 4-((1H-benzo[d][1,2,3]triazol-1-
yl)methylamino)-N-(4-oxo-2-arylthiazolidin-3-yl) 
benzamide (Ia-h) was prepared by reported method21. 




A solution of (Ia-h) (1 mmol) and benzaldehyde (1 
mmol) in dry benzene (25 mL) was refluxed for about 
10-12 h, in the presence of sodium ethoxide (1mmol),
cooled, poured into ice cold water and then acidified
with glacial acetic acid. The benzene layer was
separated, dried over CaCl2 and evaporated in vacuo to




Yield 57%,mp 176–177C,IR[ν,cm-1,KBr]:3445 
(NH),3086-3034(C-H aromatic),2965(CH2), 1690 




(CO of thiazolidinone ring), 1670 (amide C=O),1630 
(NH), 1620(C=CH-Ph), 718(C-S-C of thiazolidinone 
ring). 1H NMR[400MHz,δ,ppm, DMSO-d6]:9.66 (1H,s, 
CONH), 8.03-6.82 (18H, m,Ar-H),5.71 (2H,s, CH2), 
5.29(1H,s,SCHN),3.35-5.34(1H,s,C=CH-
Ph),3.2(1H,s,NH). 13C NMR[100MHz, δ, ppm, DMSO]:  
170.4(CO),152.6-114.3(Ar-C), 168.9(-CO of the 
ring),129.7(=C-S),125.9(=CH-Ph),75.7 (-CH2),68.6(-
CH of ring). MS (EI+) calcd for C30H24N6O2S M
+ 
532.1, found 534.7. Element Anal. Calc. for 
C30H24N6O2S M
+ 532.1: C, 67.65; H, 4.54; N, 15.78; 





Yield 55%,mp 183–184C,IR[ν,cm-1,KBr]:3445 
(NH),3086-3034(C-H aromatic),2965,2935 (CH3,CH2), 
1690 (CO of thiazolidinone ring), 1670 (amide 
C=O),1630 (NH), 1620(C=CH-Ph), 718(C-S-C of 
thiazolidinone ring). 1H NMR[400MHz,δ,ppm, 
DMSO-d6]:9.66 (1H,s, CONH), 8.03-6.82 (17H, 
m,Ar-H),5.71 (2H,s, CH2),5.29(1H,s,SCHN),3.35-
5.34(1H,s, C=CH-Ph), 3.2(1H,s,NH), 2.28 (3H, 
s,CH3).
13C NMR[100MHz, δ, ppm, DMSO]: 170.4 
(CO),152.6-114.3(Ar-C), 168.9(-CO of the 
ring),129.7(=C-S),125.9(=CH-Ph),75.7 (-CH2), 68.6(-
CH of ring), 21.6 (CH3). MS (EI
+) calcd for 
C31H26N6O2S M
+ 546.1, found 549.6. Element Anal. 
Calc. for C31H26N6O2S M
+ 546.1: C, 68.11; H, 4.79; 





oxothiazolidin- 3-yl)benzamide, IIc 
Yield 58%,mp 186–188C,IR[ν,cm-1,KBr]:3445(NH), 
3441(OH),3086-3034(C-H aromatic), 2965 (CH2), 
1690 (CO of thiazolidinone ring), 1670 (amide 
C=O),1630 (NH), 1620(C=CH-Ph), 718(C-S-C of 
thiazolidinone ring). 1H NMR[400MHz,δ,ppm, 
DMSO-d6]:9.66 (1H,s, CONH), 8.03-6.82 (17H, 
m,Ar-H),5.71 (2H,s, CH2), 5.53(1H,s,OH), 5.29 
(1H,s,SCHN),3.35-5.34(1H,s,C=CH-Ph),3.2(1H,s,NH). 
13C NMR[100MHz, δ, ppm, DMSO]: 170.4(CO), 
154.3-114.3(Ar-C), 168.9(-CO of the ring),129.7(=C-
S),125.9(=CH-Ph),75.7 (-CH2),68.6(-CH of ring). MS 
(EI+) calcd for C30H24N6O3S M
+ 548.1, found 552.3. 
Element Anal. Calc. for C30H24N6O3S M
+ 548.1: C, 
65.68; H, 4.41; N, 15.32; S, 5.84. Found: C, 65.66; H, 




Yield 61%,mp 142–144C,IR[ν,cm-1,KBr]:3445(NH), 
3443(OH),3086-3034(C-H aromatic), 2965 (CH2), 
1690 (CO of thiazolidinone ring), 1670 (amide 
C=O),1630 (NH), 1620(C=CH-Ph), 718(C-S-C of 
thiazolidinone ring). 1H NMR[400MHz,δ,ppm, 
DMSO-d6]:9.66 (1H,s, CONH), 8.03-6.82 (17H, m,Ar-
H),5.71 (2H,s, CH2), 5.49(1H,s,OH), 5.29(1H,s,SCHN), 
3.35-5.34 (1H,s,C=CH-Ph),3.2(1H,s,NH).13C N-
MR[100MHz, δ, ppm, DMSO]: 170.4(CO),159.7-
114.3(Ar-C), 168.9(-CO of the ring),129.7(=C-
S),125.9(=CH-Ph),75.7 (-CH2),68.6(-CH of ring). MS 
(EI+) calcd for C30H24N6O3S M
+ 548.1, found 552.3. 
Element Anal. Calc. for C30H24N6O3S M
+ 548.1: C, 
65.68; H, 4.41; N, 15.32; S, 5.84. Found: C, 65.67; H, 





Yield 53%,mp 154–156C,IR[ν,cm-1,KBr]:3445(NH), 
3086-3034(C-H aromatic),2965, 2928 (CH3,CH2), 
1690 (CO of thiazolidinone ring), 1670 (amide C=O), 
1630 (NH), 1620(C=CH-Ph), 1208,1156(C-O), 718 
(C-S-C of thiazolidinone ring). 1H NMR[400MHz, 
δ,ppm, DMSO-d6]: 9.66 (1H,s,CONH), 8.03-6.82 
(17H, m,Ar-H),5.71 (2H,s, CH2),5.29(1H,s,SCHN), 
3.68(3H, s,OCH3),3.35-5.34(1H,s,C=CH-Ph),3.2 
(1H,s,NH). 13C NMR[100MHz, δ, ppm, DMSO]: 
170.4(CO),164.3-114.3(Ar-C), 168.9(-CO of the 
ring),129.7(=C-S),125.9(=CH-Ph),75.7 (-CH2),68.6(-
CH of ring),57.4(OCH3). MS (EI
+) calcd for 
C31H26N6O3S M
+ 562.1, found 565.9. Element Anal. 
Calc. for C31H26N6O3S M
+ 562.1: C, 66.18; H, 4.66; 






Yield 58%,mp 171–173C,IR[ν,cm-1,KBr]:3445 
(NH),3086-3034(C-H aromatic),2965(CH2), 1690 
(CO of thiazolidinone ring), 1670 (amide C=O), 
1630 (NH), 1620(C=CH-Ph),835(Ar-Cl), 718(C-S-C 
of thiazolidinone ring). 1H NMR[400MHz,δ,ppm, 
DMSO-d6]: 9.66(1H,s,CONH), 8.03-6.82 (17H, m, 
Ar-H),5.71 (2H,s, CH2),5.29(1H,s,SCHN),3.35-5.34 
(1H,s,C=CH-Ph),3.2 (1H,s,NH).13C NMR[100MHz, 
δ, ppm, DMSO]: 170.4(CO),161.6-114.3(Ar-C), 




168.9(-CO of the ring), 137.3(Ar-Cl), 129.7(=C-
S),125.9(=CH-Ph),75.7 (-CH2),68.6(-CH of ring). MS 
(EI+) calcd for C31H26N6O3S M
+ 566.1, found 569.2. 
Element Anal. Calc. for C30H23N6O2SCl M
+ 566.1: C, 
63.54; H, 4.09; N, 14.82; S, 5.65;Cl, 6.25. Found: C, 





Yield 56%,mp 163–165C,IR[ν,cm-1,KBr]:3445(NH), 
3441,3425(OH),3086-3034(C-H aromatic),2965 (CH2), 
1690 (CO of thiazolidinone ring), 1670 (amide 
C=O),1630 (NH), 1620(C=CH-Ph), 718(C-S-C of 
thiazolidinone ring). 1H NMR[400MHz,δ,ppm, 
DMSO-d6]:9.66(1H,s,CONH), 8.03-6.82 (16H, m,Ar-
H),5.71 (2H,s, CH2), 5.49,5.38(2H,s,OH), 5.29 
(1H,s,SCHN),3.35-5.34(1H,s,C=CH-Ph),3.2(1H,s,NH). 
13C NMR[100MHz, δ, ppm, DMSO]: 170.4(CO), 
161.7-114.3(Ar-C), 168.9(-CO of the ring),129.7(=C-
S),125.9(=CH-Ph),75.7 (-CH2),68.6(-CH of ring). MS 
(EI+) calcd for C30H24N6O4S M
+ 564.1, found 567.3. 
Element Anal. Calc. for C30H24N6O4S M
+ 564.1: C, 
63.82; H, 4.28; N, 14.88; S, 5.68. Found: C, 63.81; H, 





Yield 59%,mp 158–159C,IR[ν,cm-1,KBr]:3445 
(NH),3441,3427(OH),3086-3034(C-H aromatic), 
2965 (CH2), 1690 (CO of thiazolidinone ring), 1670 
(amide C=O),1630 (NH), 1620(C=CH-Ph), 718(C-S-
C of thiazolidinone ring). 1H NMR[400MHz,δ,ppm, 
DMSO-d6]:9.66(1H,s,CONH), 8.03-6.82 (16H, m,Ar-
H),5.71 (2H,s, CH2), 5.46,5.36(2H,s,OH), 5.29 
(1H,s,SCHN),3.35-5.34(1H,s,C=CH-Ph),3.2(1H, s, 
NH). 13C NMR[100MHz, δ, ppm, DMSO]: 170.4 
(CO),155.4-114.3(Ar-C), 168.9(-CO of the 
ring),129.7(=C-S),125.9(=CH-Ph),75.7 (-CH2),68.6(-
CH of ring). MS (EI+) calcd for C30H24N6O4S M
+ 
564.1, found 567.3. Element Anal. Calc. for 
C30H24N6O4S M
+ 564.1: C, 63.82; H, 4.28; N, 14.88; 
S, 5.68. Found: C, 63.81; H, 4.27; N, 14.86; S, 5.66%. 
 




The respective benzylidene derivative, IIa-h (1 
mmol) in glacial acetic acid (10 mL), sodium acetate 
(1 g) and phenyl hydrazine (1 mL) were heated for 7 
h. The mixture was filtered hot to remove any 
insoluble material, cooled, and then water was added 
and boiled for few minutes, then it was cooled to 
afford the crude product which was purified by 






Yield 49 %,mp 143-144C,IR[ν,cm-1,KBr]: 3445, 
3224 (NH),3086-3034(C-H aromatic), 2965(CH2), 
1670 (amide C=O),1630 (NH), 1620(C=CH-





13CNMR [100 MHz, δ, ppm, 
DMSO]: 170.4 (CO),157.2,63.5, 47.2 (pyrazole ring 
C),149.6-114.3 (Ar-C), 75.7 (CH2), 68.6(CH of ring). 
MS (EI+) calcd for C36H30N8OS M
+ 622.2, found 
625.6. Element Anal. Calc. for C36H30N8OS M
+ 622.2: 
C, 69.43; H, 4.86; N, 17.99;S, 5.15. Found: C, 69.42; 





Yield 52 %,mp 139-140C,IR[ν,cm-1,KBr]: 3445,3224 
(NH),3086-3034(C-H aromatic), 2965,2938 (CH3,CH2), 
1670 (amide C=O),1630 (NH), 1620(C=CH-Ph), 
1594(C=N),718(C-S-C of thiazolidinone ring).1HNMR 
[400MHz,δ,ppm,DMSO-d6]:9.66(1H,s,CONH),8.03-
6.82 (22H,m,Ar-H),6.09(1H,s,C5H), 5.87(1H,d, J=11. 
0Hz,C3aH),5.7(2H,s,CH2),4.61(1H,d, J=11.0 Hz, 
C3H),3.2(s,1H,NH),2.28(3H,s,CH3). 
13C NMR [100 
MHz, δ, ppm,DMSO]: 170.4 (CO),157.2,63.5, 47.2 
(pyrazole ring C),153.1-114.3 (Ar-C), 75.7 (CH2), 
68.6(CH of ring),21.6 (CH3). MS (EI
+) calcd for 
C37H32N8OS M
+ 636.2, found 639.4. Element Anal. 
Calc. for C37H32N8OS M
+ 636.2: C, 69.79; H, 5.07; N, 







Yield 46 %,mp 147-149C,IR[ν,cm-1,KBr]: 3445,3224 
(NH), 3443(OH),3086-3034(C-H aromatic), 2965 




(CH2), 1670 (amide C=O),1630 (NH), 1620(C=CH-
Ph),1594(C=N),718(C-S-C of thiazolidinone ring).1 
HNMR [400MHz,δ,ppm,DMSO-d6]:9.66(1H,s,CONH), 
8.03-6.82 (22H, m, Ar-H), 6.09(1H,s,C5H), 5.87(1H,d, 
J=11.0Hz,C3aH), 5.7(2H,s,CH2), 5.56(1H,s,OH), 4.61 
(1H,d,  J=11.0Hz,C3H), 3.2(s,1H, NH). 
13CNMR  
[100 MHz, δ, ppm,DMSO]: 170.4 (CO),157.2, 
63.5,47.2 (pyrazole ring C),155.3-114.3 (Ar-C), 75.7 
(CH2), 68.6(CH of ring). MS (EI
+) calcd for 
C36H30N8O2S M
+ 638.2, found 642.5. Element Anal. 
Calc. for C36H30N8O2S M
+ 638.2: C, 67.69; H, 4.73; 





Yield 49 %,mp 143-145C,IR[ν,cm-1,KBr]: 3445, 
3224 (NH), 3447(OH),3086-3034(C-H aromatic), 
2965(CH2), 1670 (amide C=O),1630 (NH), 1620 
(C=CH-Ph),1594(C=N),718(C-S-C of thiazolidinone 
ring).1HNMR[400MHz,δ,ppm,DMSO-
d6]:9.66(1H,s,CONH),8.03-6.82 (22H, m,Ar-H),6.09 
(1H,s,C5H), 5.87(1H,d,J=11.0Hz,C3aH), 5.7(2H,s,CH2), 
5.53(1H,s,OH), 4.61 (1H,d, J=11.0Hz,C3H), 3.2(s,1H, 
NH). 13CNMR [100 MHz, δ, ppm,DMSO]: 170.4 
(CO),157.2,63.5,47.2(pyrazole ring C),159.9-114.3 
(Ar-C), 75.7 (CH2), 68.6(CH of ring). MS (EI
+) calcd 
for C36H30N8O2S M
+ 638.2, found 642.7. Element 
Anal. Calc. for C36H30N8O2S M
+ 638.2: C, 67.69; H, 
4.73; N, 17.54; S, 5.02. Found: C, 67.67; H, 4.73; N, 





Yield 45 %,mp 136-138C,IR[ν,cm-1,KBr]: 3445,3224 
(NH),3086-3034(C-H aromatic), 2965,2928 (CH3,CH2), 
1670 (amide C=O),1630 (NH), 1620(C=CH-Ph), 
1594(C=N), 1208, 1158(C-O), 718(C-S-C of 
thiazolidinone ring).1HNMR[400MHz,δ,ppm,DMSO-
d6]:9.66 (1H,s,CONH),8.03-6.82(22H,m,Ar-H),6.09 
(1H,s,C5H), 5.87(1H,d,J=11.0Hz,C3aH), 5.7(2H,s, 
CH2), 4.61(1H,d, J=11.0Hz,C3H), 3.69(3H, s,OCH3), 
3.2(s,1H, NH). 13CNMR [100 MHz, δ, ppm,DMSO]: 
170.4 (CO),157.2,63.5,47.2(pyrazole ring C),165.1-
114.3 (Ar-C), 75.7 (CH2), 68.6(CH of ring),57.3 
(OCH3). MS (EI
+) calcd for C37H32N8O2S M
+ 652.2, 
found 655.8. Element Anal. Calc. for C37H32N8O2S 
M+ 652.2: C, 68.08; H, 4.94; N, 17.17; S, 4.91. Found: 




Yield 47 %,mp 144-145C,IR[ν,cm-1,KBr]: 3445,3224 
(NH),3086-3034(C-H aromatic), 2965(CH2), 1670 
(amide C=O),1630 (NH), 1620(C=CH-Ph),1594 (C=N), 
837(Ar-Cl),718(C-S-C of thiazolidinone ring).1HNMR 
[400MHz,δ,ppm,DMSO-d6]:9.66(1H,s,CONH),8.03-
6.82(22H,m,Ar-H),6.09(1H,s,C5H), 5.87(1H,d,J=11.0Hz, 
C3aH), 5.7(2H,s,CH2), 4.61(1H,d, J=11.0Hz,C3H), 
3.2(s,1H, NH). 13CNMR [100 MHz, δ, ppm,DMSO]: 
170.4 (CO),157.2,63.5,47.2(pyrazole ring C),165.1-
114.3 (Ar-C), 137.4(Ar-Cl), 75.7 (CH2), 68.6(CH of 
ring). MS (EI+) calcd for C36H29N8OSCl M
+ 656.1, 
found 659.7. Element Anal. Calc. for C36H29N8OSCl 
M+ 656.1: C, 65.79; H, 4.45; N, 17.05;S, 4.88; Cl, 







Yield 51 %,mp 155-156C,IR[ν,cm-1,KBr]: 3445,3224 
(NH), 3443,3427(OH),3086-3034(C-H aromatic), 
2965(CH2), 1670 (amide C=O),1630 (NH), 1620(C=CH-
Ph), 1594(C=N),718(C-S-C of thiazolidinone 
ring).1HNMR[400MHz,δ,ppm,DMSO-d6]:9.66(1H,s, 
CONH),8.03-6.82 (21H, m,Ar-H), 6.09(1H,s,C5H), 
5.87(1H,d,J=11.0Hz,C3aH),5.7(2H,s,CH2), 5.52,5.42 
(2H,s, OH), 4.61(1H,d, J=11.0Hz, C3H), 3.2(s,1H, 
NH). 13CNMR [100 MHz, δ, ppm,DMSO]: 170.4 
(CO),157.2,63.5,47.2(pyrazole ring C),161.6-114.3 
(Ar-C), 75.7 (CH2), 68.6(CH of ring). MS (EI
+) calcd 
for C36H30N8O3S M
+ 654.2, found 657.8. Element 
Anal. Calc. for C36H30N8O3S M
+ 654.2: C, 66.04; H, 
4.62; N, 17.11; S, 4.90. Found: C, 66.03; H, 4.60; N, 






Yield 48 %,mp 148-149C,IR[ν,cm-1,KBr]: 3445,3224 
(NH), 3443,3428(OH),3086-3034(C-H aromatic), 2965 
(CH2), 1670 (amide C=O),1630 (NH), 1620 (C=CH-
Ph),1594(C=N),718(C-S-C of thiazolidinone ring). 
1HNMR[400MHz,δ,ppm,DMSO-d6]:9.66(1H,s,CONH), 
8.03-6.82(21H,m,Ar-H), 6.09(1H,s,C5H),5.87(1H,d, 
J=11.0Hz,C3aH),5.7(2H,s,CH2), 5.50,5.43 (2H, s,OH), 




4.61(1H,d, J=11.0Hz, C3H), 3.2(s,1H, NH). 
13CNMR 
[100 MHz, δ, ppm,DMSO]: 170.4 (CO),157.2, 63.5, 
47.2(pyrazole ring C),159.3-114.3 (Ar-C), 75.7 (CH2), 
68.6(CH of ring). MS (EI+) calcd for C36H30N8O3S M
+ 
654.2, found 657.8. Element Anal. Calc. for 
C36H30N8O3S M
+ 654.2: C, 66.04; H, 4.62; N, 17.11; 
S, 4.90. Found: C, 66.03; H, 4.60; N, 17.09; S, 4.88%. 
 
Evaluation of antimicrobial activity 
The in vitro antimicrobial activity was carried out 
by agar cup plate method22. All the synthesized 
compounds were screened for antibacterial activity 
against Staphylococcus aureus, Bacillus subtilis, 
E.coli and Klebsiella promioe at a concentration of 
50μg/ML using Chloramphenicol (0.001 mole/ml) as 
standard. The antifungal activity was investigated 
against Aspergillus niger, Botrydepladia thiobromine 
and Rhizopus nigricum using Flucanazole (0.001 
mole/ml) as standard. Inhibition was recorded by 
measuring the diameter of the inhibition zone at the 
end of 24 hr for bacteria and 48 hr for fungi. Each 
experiment was repeated thrice and the average of the 
three independent determinations was recorded. The 
results are summarized in Table I. 
 
Evaluation of antioxidant activity 
The antioxidant activity of tested 4-thiazolidinone 
derivatives was evaluated by the phosphomolybdenum 
method23. This method is based on the reduction of 
Mo(VI) to Mo(V) by the tested compounds followed 
by formation of a green phosphate/Mo(V) complex at 
acid pH. An aliquot of sample solution (100 μL, 2 
mM in DMSO) is mixed with the reagent solution (1 
mL, 0.6 M sulphuric acid, 28 mM sodium phosphate 
and 4 mM ammonium molybdate). The samples are 
incubated in a water bath at 95 °C for 90 minutes. 
Samples are cooled to room temperature and the 
absorbance was measured at 695 nm. The antioxidant 
activity was expressed relative to the antioxidant 
activity of same concentration of ascorbic acid. 
 
Results and Discussion 
The compounds (Ia-h) were reacted with 
benzaldehyde in the presence of sodium ethoxide to 
afford the new 5-benzylidene derivatives (IIa-
h).Next, compounds (IIa-h) condensed with phenyl 
hydrazine in glacial acetic acid in the presence of 
sodium acetate to give products (IVa-h) (Scheme I). 
In a typical reaction, 5-benzylidene derivatives, 
sodium acetate and phenyl hydrazine were refluxed 
for 7 h in glacial acetic acid. The crude reaction 
mixture was filtered hot to remove any insoluble 
material, and cooled. Water was added to the resulting 
mixture which was boiled for a few minutes. Finally, 
the mixture was cooled to afford the crude product 
which was then purified by column chromatography 
using the appropriate solvent system. Compounds 
(IVa-h) are presumably formed by way of the phenyl 
hydrazones (IIIa-h), followed by cyclization and 
proton transfer (Scheme I). 
Table I — Antimicrobial activity of the compounds 
Compd 
Antibacterial activity 
Zone of Inhibition in mm 
Antifungal activity 
Zone of Inhibition in mm 
K.promioe B.subtilis E.coli S.aureus A.niger B.thiobromine R.nigricum 
IIa 22 21 20 24 09 08 07 
IIb 24 23 22 26 11 10 09 
IIc 28 24 29 30 11 10 10 
IId 26 25 24 27 12 11 10 
IIe 28 28 30 30 15 14 13 
IIf 29 27 25 29 16 15 14 
IIg 31 29 27 34 16 14 13 
IIh 26 26 31 28 15 14 12 
IVa 24 23 22 26 10 09 10 
IVb 26 26 24 28 12 11 10 
IVc 30 27 30 32 13 12 12 
IVd 28 28 26 31 14 12 13 
IVe 31 30 33 32 17 16 14 
IVf 30 29 27 31 20 19 17 
IVg 32 31 29 34 16 14 14 
IVh 29 29 32 31 19 18 16 
Standard* 37 35 38 44 19 17 16 
*Standard for antibacterial: Chloramphenicol (0.001 mole/ml). 
Standard for antifungal: Flucanazole (0.001mole/ml). 




In the benzylidene derivatives (IIa-h), this AB 
system was absent, confirming that condensation had 
been taken place. Regarding compounds (IVa-h), 
their 1H-NMR spectra showed two doublets at δ 5.87 
ppm due to a proton on 3a-CH and at 4.61ppm, due to 
a proton on 3-CH, respectively. These signals reveal 
that the cyclization step had happened. 
Characteristic C=O bands appeared in the  
1690 cm-1 region in the FT-IR spectra of the 
thiazolidinones (Ia-h) and benzylidene derivatives 
(IIa-h). In the FT-IR spectra of compounds (IVa-h), 
the amide carbonyl band was absent, which clearly 
confirmed that a cyclocondensation with phenyl 
hydrazine had been taken place. Besides, the C=N 
bands of (IVa-h) were observed in the 1594cm-1 
region. Although the new compounds have stereogenic 
centers, we were not able to separate the diastereomers 
due to their similar Rf values. 
Our results have shown that the sequential 
condensation of phenyl hydrazine and compounds 
(IIa-h) containing carbonyl functionalities is a useful 
reaction for the construction of novel heterocycles of 
possible pharmacological interest. 
The structure of all the synthesized compounds was 
further confirmed by mass spectral analysis. It 
exhibited a molecular ion peak of compound is 
concurred with its molecular weight. 
 
Antimicrobial activity 
Compounds (IIa-h and IVa-h) were tested for 
antibacterial activity against Staphylococcus aureus, 
Bacillus subtilis, E.coli and klebsiella promioe. 
Amongst the compounds tested for antibacterial 
activity, the compound IVg,IVe,IVc,IIg,IIe and IIc 
were found to display considerable activity against all 
the bacteria, whereas compounds IVg was found to 
exhibit promising activity against B. subtilis and 
10h,8h,7h and 6h shows good activity against E. coli. 
The compounds IVf and IIf were found to exhibit 
promising activity against K.promioe and S.aureus. 
The compound IVf showed more antifungal activity 
than the standard flucanazole and the compound IVh 
exhibited almost equipotent activity against A. niger 
and R. nigricum and was found to be more active than 
the standard against B. thiobromine. 
 
Antioxidant activity  
Data in Figure 1 show that substituents on the 
phenyl ring have a great influence on antioxidant 
activity. In descending order the effects of the various 
substituents on the phenyl ring of the all the 
synthesized compounds were found to be: 
2,5(OH)2(IVg)> 2,5(OH)2 (IIg)> 2,3(OH)2 (IVh)> 
2,3(OH)2 (IIh) > 2-Cl (IVf)> 2-OH (IVc)> 2-OH 
(IIc)> 2-Cl (IIf)> 4-OCH3 (IVe)> 4-OH(IVd)> 4-
OCH3 (IIe)> 4-OH (IId)> 2-CH3 (IVb)> 2-CH3 
(IIb)> H(IVa)> H(IIa).Among the all the synthesized 
compounds IVg,IIg,IVh and IIh have better 
antioxidant activities than ascorbic acid. These 







Figure 1 — Antioxidant activities of novel heterocyclic derivatives
relative to ascorbic acid (Am– activity relative to ascorbic acid (AA)
on a molar basis) 
 




phenyl ring, one of them being in ortho position in 
both cases. They also posses another electron 
donating group, the presence of which obviously 
contributes to increased antioxidant activity, as the 
compounds IVd,IId,IVc and IIc with only one OH 
group in the ortho and para position did not show 
relevant antioxidant activity. 
Observing the overall data for antioxidant  
activity, it is clear that the presence of two hydroxyl 
groups has a great influence on radical scavenging 
activity. The compound IVg shows the greatest 
antioxidant activity of all investigated compounds, 
followed by the 5-arylidene-1,3-thiazolidine-4-one 
IIg, both having 2,5-(OH)2 substituents on phenyl 
ring, due to correlation of radical-scavenging effects 
of thiazolidine with the number of hydroxyl groups24. 
 
Conclusion 
In this study a series of Novel fused heterocyclic 
compounds,4-((1H-benzo[d][1,2,3]triazol-1-yl) 
methyl amino)-N-(2,3-diphenyl-5-aryl-3,3a-dihydro-
2H-pyrazolo[3,4-d]thiazol-6(5H) yl) benzamide (IVa-
h) and novel 4-((1H-benzo[d][1,2,3]triazol-1-yl) 
methylamino)-N-(5-arylidene-4-oxo-2-
phenylthiazolidin- 3-yl)benzamides (IIa-h) were 
synthesized and evaluated for their in-vitro antimicrobial 
and antioxidant activity. For all the novel compounds 
structures were elucidated by the means of various 
spectral methods.  
All synthesized compounds are active against 
Staphylococcus aureus, Bacillus subtilis, E. coli and 
Klebsiella pneumoniae. 4-((1H-Benzo[d][1,2,3] 
triazol-1-yl)methylamino)-N-(2,3-diphenyl-5-aryl-
3,3a-dihydro-2H-pyrazolo[3,4-d]thiazol-6(5H)-
yl)benzamide(IVa-h) derived from 4-((1H-
benzo[d][1,2,3] triazol-1-yl) methylamino)-N-(5-
arylidene-4-oxo-2-phenylthiazolidin-3-yl)benzamides 
(IIa-h) showed good antibacterial activities.  
Two of the fused pyrazolo-thiazol compounds 
(IVg,IVh), 5-arylidene-1,3-thiazolidine-4-one (IIg,IIh) 
proved to have better antioxidant activity in 
comparison with ascorbic acid. In conclusion, it is 
evident that the substituents on the phenyl ring have a 
great influence on antioxidant activity. 
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